Eli Lilly cuts German weight-loss syringe investment by half amid new cost-cutting law
read at STAT ↗DealNegative
Eli Lilly said it will cut its planned investment in Germany for the production of weight‑loss syringes.
The company had originally earmarked $2.67 billion, but will now invest roughly half that amount.
The reduction follows a new cost‑cutting law introduced by Health Minister Nina Warken, which mandates higher discounts from pharmaceutical firms.
The move reflects a broader slowdown in pharma spending in Germany and comes as U.S. companies report rising layoffs.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more”
read at STAT ↗687 words · retrieved Jun 4
comments(0)
5-min edit window · permanent after that